In:
Arthritis Care & Research, Wiley
Abstract:
To assess post‐COVID‐19 vaccination gout flare risk with differing baseline flare burden. Methods We prospectively studied gout patients with infrequent or frequent flares, defined as ≤1 flare/year, or ≥2 flares/year, respectively. COVID‐19 vaccine‐naïve patients managed with urate‐lowering therapy between February‐June 2021were included, and voluntarily decided on vaccination. Participants were followed for 12 weeks after enrollment or first vaccine dose. Gout flares and risk factors were compared between groups. Results Of 530 participants, 308 (58.1%) had infrequent flares, and 222 (41.9%) had frequent flares at baseline, with 248 (142 infrequent, 106 frequent) receiving two‐dose COVID‐19 vaccination. Vaccination increased cumulative flare incidence at 12 weeks in the infrequent but not the frequent flare group (26.1% vs. 10.8%, P =0.001, compared to 60.4% vs. 65.5%, P =0.428). Flare incidence in the final 4 weeks of observation decreased significantly only in the vaccinated infrequent flare group (4.3% vs. 12.0%, P =0.017). Multivariable analyses showed that vaccination (OR=2.82, 95%CI 1.50‐5.30, P =0.001), flare in the preceding year (OR=1.95, 95%CI 1.03‐3.71, P =0.04) and BMI (OR=1.09, 95%CI 1.01‐1.19, P =0.03) were independently associated with increased flare risk in the infrequent flare group. Baseline serum urate (mg/dL) was an independent risk factor in the frequent flare group (OR=1.23, 95%CI 1.05‐1.45, P =0.012). Conclusion COVID‐19 vaccination was associated with increased early gout flares only in patients with previously infrequent flares. image
Type of Medium:
Online Resource
ISSN:
2151-464X
,
2151-4658
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2016713-1
Permalink
